Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

PLACE AND ROLE OF GLYCLAZIDE IN MODERN PHARMACOTHERAPY OF TYPE 2 DIABETES

DOI: https://doi.org/10.29296/25877313-2018-12-03
Download full text PDF
Issue: 
12
Year: 
2018

S.E. Storozhenko Senior Lecturer, Department of Pharmaceutical Technology and Pharmacognosy with a Course of Postgraduate Education, Krasnoyarsk State Medical Uni-versity after Professor V. F. Voyno-Yasenetsky O.F. Veselova Ph.D. (Med.), Associate Professor, Department of Pharmacology and Pharmaceutical Consulting with the Course of Postgraduate Education, Krasnoyarsk State Medical University after Professor V.F. Voyno-Yasenetsky T.V. Potupchik Ph.D. (Med.), Associate Professor, Department of Pharmacology and Pharmaceutical Consulting with the Course of Postgraduate Education, Krasnoyarsk State Medical University after Professor V.F. Voyno-Yasenetsky E-mail: potupchik_tatyana@mail.ru E.F. Stepanova Dr.Sc. (Pharm.), Professor, Department of Pharmaceutical Technology with the Course of Medical Biotechnology, Pyatigorsk Medical and Pharmaceutical Institute Branch of Volgograd State Medical University I.V. Gatckikh Ph.D. (Med.), Associate Professor, Department of Pharmacology and Pharmaceutical Consulting with the Course of Postgraduate Education, Krasnoyarsk State Medical University after Professor V.F. Voyno-Yasenetsky A.V. Ignatyuk Teacher, Department of Management and Economics of Pharmacy with a Course of Postgraduate Education, Krasnoyarsk State Medical University after Professor V. F. Voyno-Yasenetsky

In recent years, the pharmacotherapy strategy for type 2 diabetes has undergone significant changes. This is due primarily to the expansion of the assortment of hypoglycemic drugs. Consequently, there is a possibility to choose rational therapy, which is especially important for a personified approach to the treatment of type 2 diabetes. When choosing an oral hypoglycemic agent, it is necessary to take into account not only its hypoglycemic activity, but also the ways of its metabolism and elimination, safety, additional metabolic effects. Among all groups of drugs used in the treatment of type 2 diabetes, preparations of sulfonylurea derivatives have not lost their relevance and, moreover, have proved to be effective and safe means, widely used in clinical practice. The most popular preparation of this group is glyclazide, which is significantly distinguished by its positive properties. Gliclazide is a hypoglycemic-safe drug, able to bind free radicals, thus counteracting oxidative stress. Given the importance of preventing complications of cardiovascular pathology, it is important to note the safety of glyclazide in patients with type 2 diabetes with a very high cardiovascular risk. Thus, gliclazide meets all the requirements for preparations for the treatment of type 2 diabetes.

Keywords: 
diabetes mellitus type 2
derivatives of sulfonylureas
gliclazide

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Algoritmy spetsializirovannoj meditsinskoj pomoschi bol'nym saharnym diabetom / Pod red. I.I. Dedova, M.V. Shestakovoj, A.Ju. Majorova. 8-j vyp. M. 2017. S. 8-20.
  2. Ahmedova E.A., Dudinskaja E.N., Mardanov B.U., Abdal-kina E.N., Kanorskij S.G. Kontrol' glikemii pri saharnom diabete: obzor mezhdunarodnyh issledovanij po kardiologicheskoj bezopasnosti saharosnizhajuschih pre-paratov // Mezhdunarodnyj zhurnal serdtsa i sosudistyh zabolevanij. 2016. T. 11. № 4. S. 8-14.
  3. Inzucchi S.E., Bergenstal R.M. Management of Hypergly-cemia in Type 2 Diabetes, 2015: A Patient-Centered Ap-proach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes // Diabetes Care. 2014. 38 (1): 140–149.
  4. Evsina M.G., Chepisova M.V., Vishneva E.M. Organo-protektivnye svojstva osnovnyh grupp saharosnizhaju-schih lekarstvennyh preparatov // Sovremennye problemy nauki i obrazovanija. 2015. № 6.
  5. Rudoj A.S., Chernysh O.V., Pashkevich P.P. Osobennosti lechenija saharnogo diabeta 2-go tipa // Voennaja meditsina. 2016. № 1. S. 114-122.
  6. IDF Diabetes Atlas. Eight edition, 2017 update. Online version of IDF Diabetes Atlas. Available from: http://www.idf.org/diabetesatlas.
  7. Kalashnikova M.F., Belousov D.Ju., Kantemirova M.A., Antsiferov M.B. Sravnitel'noe farmakoepidemiologi-cheskoe issledovanie potreblenija saharosnizhajuschih lekarstvennyh preparatov u bol'nyh saharnym diabe-tom 2-go tipa v gorode Moskve // Saharnyj diabet. 2016. T. 19. № 3. S. 260-272.
  8. Ananicheva E.V., Skal'skij S.V., Shukil' L.V., Petunina M.V., Paruchikova S.A., Pajmanov I.V. Farmakoepidemiologiches-koe issledovanie terapevticheskogo kontrolja saharnogo diabeta 2-go tipa v Omske // Problemy endokrinologii. 2016. T. 62. № 1. S. 25-34.
  9. Podachina S.V. Gliklazid MV: kontrol' diabeta i ego oslozhnenij. Effektivnaja farmakoterapija // Endokrino-logija. Spetsvypusk. «Saharnyj diabet». 2017. № 9. S. 8-12.
  10. Koziolova N.A., Chernjavina A.I., Poljanskaja E.A. Vybor saharosnizhajuschih preparatov u bol'nyh saharnym dia-betom 2-go tipa ochen' vysokogo serdechno-sosudistogo riska (ch. 1) // Arterial'naja gipertenzija. 2016. T. 22. № 4. S. 330-348.
  11. Mansour Alsharidah, Metab. Algeffari, Abdel-Moneim Hafez Abdel-Moneim, Mohamed Faisal Lutfi, Haila Alshelowi. Effect of combined gliclazide/metformin treatment on oxidative stress, lipid profile, and hepatorenal functions in type 2 diabetic patients // Saudi Pharmaceutical Journal. 2018. № 26. R. 1–6.
  12. Alessandro Mantovani, Giorgio Grani, Laura Chioma, Giuseppe Vancieri, Ilaria Giordani, Roberta Rendina, Maria Elena Rinaldi, Aikaterini Andreadi, Carmela Coccaro, Chiara Boccardo, Costanza Fraenza, Giuliano Bertazzoni, Alfonso Bellia, Giacomo Zoppini, Giovanni Targher, Marco Giorgio Baroni, Davide Lauro, Massimino D’Armiento, Enzo Bonora. Severe hypoglycemia in patients with known diabetes requiring emergency department care: A report from an Italian multicenter study // Journal of Clinical & Translational Endocrinology. 2016. № 5. R. 46–52.
  13. Mkrtumjan A.M. Diabeton MV – obschepriznannyj vysoko-effektivnyj i bezopasnyj preparat sul'fonilmocheviny dlja mono- i kombinirovannoj terapii s metforminom. Effektivnaja farmakoterapija // Endokrinologija. Spets-vypusk. «Saharnyj diabet». 2016. № 12. S. 16-20.